<DOC>
	<DOCNO>NCT00505895</DOCNO>
	<brief_summary>The goal clinical research study learn difference transplant outcomes two different dos melphalan give combination fludarabine follow transfusion relate unrelated volunteer donor 's peripheral blood bone marrow progenitor cell ( allogeneic stem cell transplant ) patient multiple myeloma . This study also look whether treatment antibody call rituximab specific type lymphocyte ( B cell ) reduce risk develop graft versus host disease transplant . The safety treatment also compare .</brief_summary>
	<brief_title>FM 140 v FM100 Study Patients With Multiple Myeloma</brief_title>
	<detailed_description>Fludarabine chemotherapy drug use various disease . Melphalan chemotherapy drug widely use treatment multiple myeloma many year . Before begin therapy , patient complete work-up . This include bone marrow aspiration biopsy , bone survey , blood test , test check heart lung function . All patient receive tacrolimus methotrexate prevent graft-versus-host disease . Patients study randomly pick ( toss coin ) one two treatment group . There equal chance patient either group . Patients first group receive fludarabine vein every day four day . On fourth day , patient receive dose melphalan vein 20 minute . On follow day , patient receive donor cell infusion catheter . Patients second group receive fludarabine vein every day four day . Patients group receive low dose melphalan vein 20 minute . After last dose fludarabine , patient receive donor cell infusion catheter next day . If unrelated mismatch donor , receive drug ATG ( Thymoglobulin ) vein 6 hour Days -3 , -2 , -1 ( 3 day transplant ) , prevent graft versus host disease ( GVHD ) help engraftment . Patients group receive monoclonal antibody call rituximab weekly start fifth day stem cell transplant total 4 dos . Patients remain hospital 4-6 week Houston Medical Center area least 100 day transplantation . Patients whose disease get bad take study . These patient continue follow survival . This investigational study . All drug use study commercially available . The FDA approve melphalan treatment myeloma . Fludarabine approve treatment myeloma use year way prepare patient transplant . About 30 60 patient take part study . About 45 patient enrol M. D. Anderson .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients Multiple Myeloma follow disease category : ) Primary Refractory consider poor candidate autologous transplant , b ) Remission Consolidation patient Chromosome 13 abnormality plasma cell leukemia , c ) All relapse patient . 2 . Age 70 year . 3 . Related unrelated donor HLAcompatible least 9/10 allele ( A , B , C , DRB1 DQ ) molecular technique . 4 . Zubrod Performance Score ( PS ) &lt; 2 . 5 . Life expectancy severely limited concomitant illness . Left ventricular ejection fraction &gt; 40 % . No uncontrolled arrhythmias symptomatic cardiac disease . Forced expiratory volume 1 second ( FEV1 ) , force vital capacity ( FVC ) diffuse capacity lung carbon monoxide ( DLCO ) &gt; 40 % . 6 . Patient donor guardian willing able sign inform consent . 1 ) Patients active central nervous system ( CNS ) disease ineligible study document clinical symptom and/or test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludara</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Stem Cell Infusion</keyword>
	<keyword>Stem Cell Transfusion</keyword>
	<keyword>SCT</keyword>
	<keyword>Allogeneic Peripheral Blood Stem Cell Transfusion</keyword>
	<keyword>APBSCT</keyword>
	<keyword>Bone Marrow Transplantation</keyword>
	<keyword>BMT</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Rituximab</keyword>
	<keyword>FM140</keyword>
	<keyword>FM100</keyword>
</DOC>